Kinoxis Therapeutics Pty is an early stage biotechnology company based in Australia that is working to progress the development of a range of novel therapeutic compounds for the treatment of substance use disorders and other CNS conditions. The company has licensed these compounds from the University of Sydney, with the lead candidate demonstrating potent anti-addictive and prosocial effects in a number of different animal models and is progressing through pre-clinical testing.

Substance use disorders, including the abuse of alcohol, illicit and prescription drugs, represent a considerable treatment challenge for health care professionals. There are currently only a limited number of drugs approved for substance use disorders and no approved pharmacological treatments for methamphetamine or cocaine use disorders.

For further information, please contact Hugh Alsop.